How would you approach a patient who progressed on immunotherapy for merkel cell carcinoma?   

Checkpoint inhibitors have demonstrated durable responses in clinical trials, which was never seen with cytotoxic chemotherapy in the past. What are the second line  options for patients who unfortunately fail to respond to immunotherapy?

Answer from: Medical Oncologist at Academic Institution